IMMUNOCELLULAR THERAPEUTICS (IMUC) Stock Price & Overview

NYSEARCA:IMUC • US4525362046

Current stock price

0.053
-0.17 (-75.91%)
Last:

The current stock price of IMUC is 0.053 null. Today IMUC is down by -75.91%. In the past month the price decreased by -74.76%. In the past year, price decreased by -86.75%.

IMUC Key Statistics

52-Week Range0.03 - 0.55
Current IMUC stock price positioned within its 52-week range.
1-Month Range0.051 - 0.255
Current IMUC stock price positioned within its 1-month range.
Market Cap
2.223M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.45
Dividend Yield
N/A

IMUC Stock Performance

Today
-75.91%
1 Week
-76.34%
1 Month
-74.76%
3 Months
-77.92%
Longer-term
6 Months -80.00%
1 Year -86.75%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

IMUC Stock Chart

IMMUNOCELLULAR THERAPEUTICS / IMUC Daily stock chart

IMUC Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to IMUC. When comparing the yearly performance of all stocks, IMUC is a bad performer in the overall market: 99.67% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
IMUC Full Technical Analysis Report

IMUC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IMUC. The financial health of IMUC is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IMUC Full Fundamental Analysis Report

IMUC Earnings

Next Earnings DateN/A
Last Earnings DateN/A
IMUC Earnings History

IMUC Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y-100%
Revenue Next YearN/A
IMUC Forecast & Estimates

IMUC Financial Highlights

Over the last trailing twelve months IMUC reported a non-GAAP Earnings per Share(EPS) of -1.4500000000000002. The EPS increased by 86.7% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-6.11M
Industry RankSector Rank
PM (TTM) N/A
ROA -159.47%
ROE -178.18%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.02%
Sales Q2Q%N/A
EPS 1Y (TTM)86.7%
Revenue 1Y (TTM)N/A
IMUC financials

IMUC Ownership

Ownership
Inst Owners4.29%
Shares41.94M
Float40.68M
Ins Owners1.01%
Short Float %0%
Short Ratio0
IMUC Ownership

About IMUC

Company Profile

ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.

Company Info

IMMUNOCELLULAR THERAPEUTICS

23622 CALABASAS ROAD SUITE 300

CALABASAS CA 91302

CEO: Anthony Gringeri

Phone: 818-264-2300

IMMUNOCELLULAR THERAPEUTICS / IMUC FAQ

What does IMUC do?

ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.


Can you provide the latest stock price for IMMUNOCELLULAR THERAPEUTICS?

The current stock price of IMUC is 0.053 null. The price decreased by -75.91% in the last trading session.


Does IMUC stock pay dividends?

IMUC does not pay a dividend.


What is the ChartMill technical and fundamental rating of IMUC stock?

IMUC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.